Myeloma Mentors: Charting New Paths in Relapsed/Refractory Multiple Myeloma Care

Myeloma Mentors: Charting New Paths in Relapsed/Refractory Multiple Myeloma Care

earn up to 2.25 ACCME credits
About The Program
Overview
Learning Objectives
CME Information
Faculty and Disclosures
Instructions

Program Overview

Advances in bispecific antibodies (BsAbs) and CAR T-cell therapy have transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM). However, with rapid developments come significant challenges: integrating novel agents into patient-specific care plans, sequencing therapies appropriately, and managing unique toxicities such as cytokine release syndrome (CRS) and ICANS. Variability in protocols and transitions between academic and community oncology settings further contribute to fragmented care.

In partnership with the University of Colorado Hematology Division, this accredited educational initiative brings together leading hematology experts and community clinicians to address these critical gaps. Through interactive mentorship sessions, case-based discussions, and enduring webcasts, participants will gain the tools needed to optimize therapy selection, sequencing, and toxicity management in RRMM. A dedicated provider toolkit and non-certified social media broadcasts will further extend the reach and impact of the program, supporting equitable access to evidence-based care across diverse practice environments.

By fostering collaboration between academic centers and community oncology practices, this program empowers clinicians to improve continuity of care, implement best practices, and ultimately enhance patient outcomes.

Target Audience

This educational program is directed at hematologists/oncologists in both the academic and community setting as well as advanced practice providers and other HCPs involved in the management of patients with RRMM.

Supporter Acknowledgement

This educational activity is supported by an educational grant from
Johnson & Johnson.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Differentiate between BCMA and GPRC5D-targeting BsAbs based on specific mechanisms of action, efficacy data, and safety profiles to select optimal agents for individual patients with RRMM.
  • Construct patient-specific treatment sequences incorporating BsAbs into existing treatment plans based on prior treatments, disease characteristics, and comorbidities.
  • Implement evidence-based strategies for mitigating and managing CRS and neurological toxicities associated with BsAbs in both inpatient and outpatient settings, including step-up dosing protocols, specific monitoring parameters, and thresholds for intervention.
  • Formulate a structured communication plan between academic and community practitioners to ensure safe transitions of care for patients receiving BsAbs.

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education, in collaboration with The University of Colorado Division of Hematology.

Physician Accreditation Statement

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium CE. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 2.25 contact hours including 0.0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Iridium CE do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
The planners and managers have the following relevant financial relationships with ineligible companies:

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

The planners and managers at Iridium CE have no relevant financial relationships to disclose.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Joseph Mikhael, MD, Med, FRCPC,
FACP, FASCO
Professor, Translational Genomics Research Institute 
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Phoenix, Arizona
Consulting Fee (e.g, Advisory Board):
BMS, Janssen, Menarini, Sanofi
Jorge Monge Urrea, MD
Assistant Professor of Medicine
University of Colorado
Aurora, Colorado
Consulting Fee (e.g., Advisory Board):
Johnson & Johnson, Pfizer
Dan Sherbenou,
MD, PhD
Associate Professor, Medicine – Hematology
University of Colorado
Aurora, Colorado
Disclosures:
Nothing to Disclose
Kaylee Timlin,
MSN, BS
Instructor of Medicine, Hematology
University of Colorado
Aurora, Colorado
Disclosures:
Nothing to Disclose
Join leading experts and peers to advance care in relapsed/refractory multiple myeloma (RRMM).
Stay ahead in the rapidly evolving treatment landscape of relapsed/refractory multiple myeloma (RRMM). With bispecific antibodies (BsAbs) and CAR T-cell therapies transforming care, healthcare professionals face new challenges in sequencing therapies, managing toxicities, and ensuring continuity across academic and community settings.

This CME-certified program brings together expert faculty and community clinicians through interactive mentorship sessions featuring case-based discussions. Participants will gain practical, evidence-based insights to strengthen decision-making and enhance patient care.

All sessions will be interactive, case-based, and HIPAA compliant.

Target Audience

This educational program is directed at hematologists/oncologists in both the academic and community setting as well as advanced practice providers and other HCPs involved in the management of patients with RRMM. 

Dates

Understanding the Role of BsAbs in RRMM
October 23, 2025 5 pm ET / 4 pm CT / 3 pm MT / 2 pm PT 
LIVE ON ZOOM
Upon completion of this activity, the participant should be able to:
  • Differentiate between BCMA and GPRC5D-targeting BsAbs based on specific mechanisms of action, efficacy data, and safety profiles to select optimal agents for individual patients with RRMM.

0.75 AMA PRA Category 1 Credit
0.75 ANCC Credit

Optimizing Treatment Sequencing and Patient Selection
November 6, 2025 5 pm ET / 4 pm CT / 3 pm MT / 2 pm PT 
LIVE ON ZOOM
Upon completion of this activity, the participant should be able to:
  • Construct patient-specific treatment sequences incorporating BsAbs into existing treatment plans based on prior treatments, disease characteristics, and comorbidities

0.75 AMA PRA Category 1 Credit
0.75 ANCC Credit

Optimizing Bispecific Antibody Therapy Across Care Settings
November 20, 2025 3 pm ET / 2 pm CT / 1 pm MT / 12 pm PT*
LIVE ON ZOOM
Upon completion of this activity, the participant should be able to:
  • Implement evidence-based strategies for mitigating and managing CRS and neurological toxicities associated with BsAbs in both inpatient and outpatient settings, including step-up dosing protocols, specific monitoring parameters, and thresholds for intervention.
  • Formulate a structured communication plan between academic and community practitioners to ensure safe transitions of care for patients receiving BsAbs.

0.75 AMA PRA Category 1 Credit
0.75 ANCC Credit

*note earlier time

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:
  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 70% or higher
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

System Requirements

System requirements
This educational activity is supported by an educational grant from Johnson & Johnson.

Maximum Credit Amount: 2.25

Credit Type: ACCME, ANCC
Release: 10/23/2025
Expiration: 11/20/2025